{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:41:09Z","timestamp":1772840469132,"version":"3.50.1"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA233610"],"award-info":[{"award-number":["CA233610"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s12265-020-09992-5","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T12:02:51Z","timestamp":1586174571000},"page":"402-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors"],"prefix":"10.1007","volume":"13","author":[{"given":"Sherry-Ann","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan C.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"issue":"1","key":"9992_CR1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang, J., Yang, P. L., & Gray, N. S. (2009). Targeting cancer with small molecule kinase inhibitors. Nature Reviews. Cancer, 9(1), 28.","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"9992_CR2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018). Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of Hematology & Oncology, 11(1), 39.","journal-title":"Journal of Hematology & Oncology"},{"issue":"4","key":"9992_CR3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","volume":"1","author":"P Cohen","year":"2002","unstructured":"Cohen, P. (2002). Protein kinases\u2014the major drug targets of the twenty-first century? Nature Reviews. Drug Discovery, 1(4), 309.","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"18","key":"9992_CR4","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., et al. (2016). Fulminant myocarditis with combination immune checkpoint blockade. The New England Journal of Medicine, 375(18), 1749\u20131755.","journal-title":"The New England Journal of Medicine"},{"issue":"35","key":"9992_CR5","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi, J. J., & Deininger, M. (2015). Tyrosine kinase inhibitor\u2013associated cardiovascular toxicity in chronic myeloid leukemia. Journal of Clinical Oncology, 33(35), 4210.","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"9992_CR6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","volume":"7","author":"T Force","year":"2007","unstructured":"Force, T., Krause, D. S., & Van Etten, R. A. (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews. Cancer, 7(5), 332.","journal-title":"Nature Reviews. Cancer"},{"issue":"12","key":"9992_CR7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrclinonc.2015.168","volume":"12","author":"SA Brown","year":"2015","unstructured":"Brown, S. A., Sandhu, N., & Herrmann, J. (2015). Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nature Reviews. Clinical Oncology, 12(12), 718\u2013731.","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"1","key":"9992_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cpt.552","volume":"101","author":"SA Brown","year":"2017","unstructured":"Brown, S. A., Nhola, L., & Herrmann, J. (2017). Cardiovascular toxicities of small molecule tyrosine kinase inhibitors: an opportunity for systems-based approaches. Clinical Pharmacology and Therapeutics, 101(1), 65\u201380.","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"7","key":"9992_CR9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","volume":"36","author":"P Wu","year":"2015","unstructured":"Wu, P., Nielsen, T. E., & Clausen, M. H. (2015). FDA-approved small-molecule kinase inhibitors. Trends in Pharmacological Sciences, 36(7), 422\u2013439.","journal-title":"Trends in Pharmacological Sciences"},{"issue":"1","key":"9992_CR10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","volume":"118","author":"MH Chen","year":"2008","unstructured":"Chen, M. H., Kerkel\u00e4, R., & Force, T. (2008). Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation., 118(1), 84\u201395.","journal-title":"Circulation."},{"issue":"2","key":"9992_CR11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd3252","volume":"10","author":"T Force","year":"2011","unstructured":"Force, T., & Kolaja, K. L. (2011). Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nature Reviews. Drug Discovery, 10(2), 111.","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"2","key":"9992_CR12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.taap.2009.12.032","volume":"244","author":"BB Hasinoff","year":"2010","unstructured":"Hasinoff, B. B. (2010). The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicology and Applied Pharmacology, 244(2), 190\u2013195.","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"2","key":"9992_CR13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.taap.2010.08.026","volume":"249","author":"BB Hasinoff","year":"2010","unstructured":"Hasinoff, B. B., & Patel, D. (2010). The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicology and Applied Pharmacology, 249(2), 132\u2013139.","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"11","key":"9992_CR14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1634\/theoncologist.2009-0142","volume":"14","author":"V Roy","year":"2009","unstructured":"Roy, V., & Perez, E. A. (2009). Beyond trastuzumab: Small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist., 14(11), 1061\u20131069.","journal-title":"Oncologist."},{"issue":"2","key":"9992_CR15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews. Molecular Cell Biology, 2(2), 127.","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"5","key":"9992_CR16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/ncb3149","volume":"17","author":"G D\u2019Uva","year":"2015","unstructured":"D\u2019Uva, G., Aharonov, A., Lauriola, M., Kain, D., Yahalom-Ronen, Y., Carvalho, S., et al. (2015). ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nature Cell Biology, 17(5), 627.","journal-title":"Nature Cell Biology"},{"issue":"13","key":"9992_CR17","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.122249299","volume":"99","author":"C \u00d6zcelik","year":"2002","unstructured":"\u00d6zcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., H\u00fcbner, N., et al. (2002). Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proceedings of the National Academy of Sciences, 99(13), 8880\u20138885.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"2","key":"9992_CR18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yjmcc.2006.04.007","volume":"41","author":"Y Kuramochi","year":"2006","unstructured":"Kuramochi, Y., Guo, X., & Sawyer, D. B. (2006). Neuregulin activates erbB2-dependent src\/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. Journal of Molecular and Cellular Cardiology, 41(2), 228\u2013235.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"5","key":"9992_CR19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., et al. (2002). ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine, 8(5), 459.","journal-title":"Nature Medicine"},{"issue":"15","key":"9992_CR20","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1080\/15384101.2015.1063292","volume":"14","author":"G D'Uva","year":"2015","unstructured":"D'Uva, G., & Tzahor, E. (2015). The key roles of ERBB2 in cardiac regeneration. Cell Cycle, 14(15), 2383.","journal-title":"Cell Cycle"},{"issue":"6020","key":"9992_CR21","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.1200708","volume":"331","author":"ER Porrello","year":"2011","unstructured":"Porrello, E. R., Mahmoud, A. I., Simpson, E., Hill, J. A., Richardson, J. A., Olson, E. N., et al. (2011). Transient regenerative potential of the neonatal mouse heart. Science., 331(6020), 1078\u20131080.","journal-title":"Science."},{"key":"9992_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/rp.59.1.1","volume":"59","author":"A Negro","year":"2004","unstructured":"Negro, A., Brar, B. K., & Lee, K. F. (2004). Essential roles of Her2\/erbB2 in cardiac development and function. Recent Progress in Hormone Research, 59, 1\u201312.","journal-title":"Recent Progress in Hormone Research"},{"issue":"9","key":"9992_CR23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.semcdb.2010.09.011","volume":"21","author":"P Sanchez-Soria","year":"2010","unstructured":"Sanchez-Soria, P., & Camenisch, T. D. (2010). ErbB signaling in cardiac development and disease. Seminars in Cell & Developmental Biology, 21(9), 929\u2013935.","journal-title":"Seminars in Cell & Developmental Biology"},{"issue":"7","key":"9992_CR24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ctrv.2009.06.007","volume":"35","author":"H Azim","year":"2009","unstructured":"Azim, H., Azim, H. A., & Escudier, B. (2009). Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treatment Reviews, 35(7), 633\u2013638.","journal-title":"Cancer Treatment Reviews"},{"issue":"3","key":"9992_CR25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdr294","volume":"23","author":"D Lenihan","year":"2012","unstructured":"Lenihan, D., Suter, T., Brammer, M., Neate, C., Ross, G., & Baselga, J. (2012). Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Annals of Oncology, 23(3), 791\u2013800.","journal-title":"Annals of Oncology"},{"issue":"3","key":"9992_CR26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdr294","volume":"23","author":"D Lenihan","year":"2011","unstructured":"Lenihan, D., Suter, T., Brammer, M., Neate, C., Ross, G., & Baselga, J. (2011). Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Annals of Oncology, 23(3), 791\u2013800.","journal-title":"Annals of Oncology"},{"issue":"11","key":"9992_CR27","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2004.08.066","volume":"44","author":"LP Grazette","year":"2004","unstructured":"Grazette, L. P., Boecker, W., Matsui, T., Semigran, M., Force, T. L., Hajjar, R. J., et al. (2004). Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. Journal of the American College of Cardiology, 44(11), 2231\u20132238.","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"9992_CR28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/fon.14.184","volume":"11","author":"MA Sendur","year":"2015","unstructured":"Sendur, M. A., Aksoy, S., & Altundag, K. (2015). Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab. Future Oncology, 11(1), 13\u201315.","journal-title":"Future Oncology"},{"key":"9992_CR29","doi-asserted-by":"crossref","unstructured":"Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunology, Immunotherapy. 2006;55(6):717.","DOI":"10.1007\/s00262-005-0058-x"},{"issue":"10","key":"9992_CR30","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1185\/03007995.2012.728132","volume":"28","author":"MA Sendur","year":"2012","unstructured":"Sendur, M. A., Aksoy, S., & Altundag, K. (2012). Pertuzumab in HER2-positive breast cancer. Current Medical Research and Opinion, 28(10), 1709\u20131716.","journal-title":"Current Medical Research and Opinion"},{"issue":"5","key":"9992_CR31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","volume":"3","author":"R Nahta","year":"2006","unstructured":"Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006). Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Reviews. Clinical Oncology, 3(5), 269.","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"2","key":"9992_CR32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-012-2103-8","volume":"134","author":"C Fedele","year":"2012","unstructured":"Fedele, C., Riccio, G., Malara, A. E., D\u2019Alessio, G., & De Lorenzo, C. (2012). Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Research and Treatment, 134(2), 595\u2013602.","journal-title":"Breast Cancer Research and Treatment"},{"issue":"8","key":"9992_CR33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1185\/03007995.2013.807232","volume":"29","author":"MA Sendur","year":"2013","unstructured":"Sendur, M. A., Aksoy, S., & Altundag, K. (2013). Cardiotoxicity of novel HER2-targeted therapies. Current Medical Research and Opinion, 29(8), 1015\u20131024.","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"9992_CR34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnology, 26(1), 127.","journal-title":"Nature Biotechnology"},{"issue":"1","key":"9992_CR35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","volume":"2","author":"R Kerkela","year":"2009","unstructured":"Kerkela, R., Woulfe, K. C., Durand, J. B., Vagnozzi, R., Kramer, D., Chu, T. F., et al. (2009). Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clinical and Translational Science, 2(1), 15\u201325.","journal-title":"Clinical and Translational Science"},{"issue":"10","key":"9992_CR36","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.freeradbiomed.2007.02.011","volume":"42","author":"M Thirunavukkarasu","year":"2007","unstructured":"Thirunavukkarasu, M., Juhasz, B., Zhan, L., Menon, V. P., Tosaki, A., Otani, H., et al. (2007). VEGFR1 (Flt-1+\/\u2212) gene knockout leads to the disruption of VEGF-mediated signaling through the nitric oxide\/heme oxygenase pathway in ischemic preconditioned myocardium. Free Radical Biology & Medicine, 42(10), 1487\u20131495.","journal-title":"Free Radical Biology & Medicine"},{"issue":"2","key":"9992_CR37","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1172\/JCI39434","volume":"120","author":"V Chintalgattu","year":"2010","unstructured":"Chintalgattu, V., Ai, D., Langley, R. R., Zhang, J., Bankson, J. A., Shih, T. L., et al. (2010). Cardiomyocyte PDGFR-\u03b2 signaling is an essential component of the mouse cardiac response to load-induced stress. The Journal of Clinical Investigation, 120(2), 472\u2013484.","journal-title":"The Journal of Clinical Investigation"},{"issue":"5","key":"9992_CR38","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1161\/01.HYP.0000215207.54689.31","volume":"47","author":"Y Izumiya","year":"2006","unstructured":"Izumiya, Y., Shiojima, I., Sato, K., Sawyer, D. B., Colucci, W. S., & Walsh, K. (2006). Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension., 47(5), 887\u2013893.","journal-title":"Hypertension."},{"key":"9992_CR39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","volume":"2","author":"RM Touyz","year":"2018","unstructured":"Touyz, R. M., & Herrmann, J. (2018). Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol., 2, 13.","journal-title":"NPJ Precis Oncol."},{"issue":"9604","key":"9992_CR40","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., et al. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. The Lancet., 370(9604), 2011\u20132019.","journal-title":"The Lancet."},{"issue":"11","key":"9992_CR41","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/cncr.23460","volume":"112","author":"AY Khakoo","year":"2008","unstructured":"Khakoo, A. Y., Kassiotis, C. M., Tannir, N., Plana, J. C., Halushka, M., Bickford, C., et al. (2008). Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer: Interdisciplinary International Journal of the American Cancer Society., 112(11), 2500\u20132508.","journal-title":"Cancer: Interdisciplinary International Journal of the American Cancer Society."},{"issue":"9","key":"9992_CR42","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","volume":"19","author":"M Telli","year":"2008","unstructured":"Telli, M., Witteles, R., Fisher, G., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Annals of Oncology, 19(9), 1613\u20131618.","journal-title":"Annals of Oncology"},{"issue":"7","key":"9992_CR43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrm2199","volume":"8","author":"D Ron","year":"2007","unstructured":"Ron, D., & Walter, P. (2007). Signal integration in the endoplasmic reticulum unfolded protein response. Nature Reviews. Molecular Cell Biology, 8(7), 519.","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"5711","key":"9992_CR44","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1126\/science.1101902","volume":"307","author":"M Boyce","year":"2005","unstructured":"Boyce, M., Bryant, K. F., Jousse, C., Long, K., Harding, H. P., Scheuner, D., et al. (2005). A selective inhibitor of eIF2\u03b1 dephosphorylation protects cells from ER stress. Science., 307(5711), 935\u2013939.","journal-title":"Science."},{"issue":"Suppl 13","key":"9992_CR45","doi-asserted-by":"crossref","first-page":"S1581","DOI":"10.21037\/jtd.2018.02.79","volume":"10","author":"C Donini","year":"2018","unstructured":"Donini, C., D\u2019Ambrosio, L., Grignani, G., Aglietta, M., & Sangiolo, D. (2018). Next generation immune-checkpoints for cancer therapy. Journal of Thoracic Disease, 10(Suppl 13), S1581.","journal-title":"Journal of Thoracic Disease"},{"issue":"16","key":"9992_CR46","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., et al. (2018). Myocarditis in patients treated with immune checkpoint inhibitors. Journal of the American College of Cardiology, 71(16), 1755\u20131764.","journal-title":"Journal of the American College of Cardiology"},{"issue":"10124","key":"9992_CR47","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018). Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet., 391(10124), 933.","journal-title":"The Lancet."},{"issue":"12","key":"9992_CR48","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., et al. (2003). Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nature Medicine, 9(12), 1477.","journal-title":"Nature Medicine"},{"issue":"6","key":"9992_CR49","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., et al. (2013). Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood., 122(6), 863\u2013871.","journal-title":"Blood."},{"issue":"4","key":"9992_CR50","first-page":"1314","volume":"7","author":"C Chen","year":"2014","unstructured":"Chen, C., Liu, J.-B., Bian, Z.-P., Xu, J.-D., Wu, H.-F., Gu, C.-R., et al. (2014). Cardiac troponin I is abnormally expressed in non-small cell lung cancer tissues and human cancer cells. International Journal of Clinical and Experimental Pathology, 7(4), 1314.","journal-title":"International Journal of Clinical and Experimental Pathology"},{"issue":"6220","key":"9992_CR51","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n, M., Fagerberg, L., Hallstr\u00f6m, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., et al. (2015). Tissue-based map of the human proteome. Science., 347(6220), 1260419.","journal-title":"Science."},{"issue":"1","key":"9992_CR52","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-011-8294-7","volume":"42","author":"MF Cusick","year":"2012","unstructured":"Cusick, M. F., Libbey, J. E., & Fujinami, R. S. (2012). Molecular mimicry as a mechanism of autoimmune disease. Clinical Reviews in Allergy and Immunology, 42(1), 102\u2013111.","journal-title":"Clinical Reviews in Allergy and Immunology"},{"key":"9992_CR53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fped.2014.00085","volume":"2","author":"R Root-Bernstein","year":"2014","unstructured":"Root-Bernstein, R. (2014). Rethinking molecular mimicry in rheumatic heart disease and autoimmune myocarditis: laminin, collagen IV, CAR, and B1AR as initial targets of disease. Frontiers in Pediatrics, 2, 85.","journal-title":"Frontiers in Pediatrics"},{"issue":"12","key":"9992_CR54","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999). B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Medicine, 5(12), 1365.","journal-title":"Nature Medicine"},{"issue":"5502","key":"9992_CR55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., et al. (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science., 291(5502), 319\u2013322.","journal-title":"Science."},{"issue":"4","key":"9992_CR56","doi-asserted-by":"crossref","first-page":"e0124059","DOI":"10.1371\/journal.pone.0124059","volume":"10","author":"B Baban","year":"2015","unstructured":"Baban, B., Liu, J. Y., Qin, X., Weintraub, N. L., & Mozaffari, M. S. (2015). Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153. PLoS One, 10(4), e0124059.","journal-title":"PLoS One"},{"issue":"6","key":"9992_CR57","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxq026","volume":"22","author":"J Wang","year":"2010","unstructured":"Wang, J., Okazaki, I.-m., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., et al. (2010). PD-1 deficiency results in the development of fatal myocarditis in MRL mice. International Immunology, 22(6), 443\u2013452.","journal-title":"International Immunology"},{"issue":"3","key":"9992_CR58","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","volume":"101","author":"VA Love","year":"2007","unstructured":"Love, V. A., Grabie, N., Duramad, P., Stavrakis, G., Sharpe, A., & Lichtman, A. (2007). CTLA-4 ablation and interleukin-12\u2013driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circulation Research, 101(3), 248\u2013257.","journal-title":"Circulation Research"},{"issue":"1","key":"9992_CR59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., et al. (2016). Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. Journal for Immunotherapy of Cancer, 4(1), 50.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"9992_CR60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","volume":"5","author":"TG Norwood","year":"2017","unstructured":"Norwood, T. G., Westbrook, B. C., Johnson, D. B., Litovsky, S. H., Terry, N. L., McKee, S. B., et al. (2017). Smoldering myocarditis following immune checkpoint blockade. Journal for Immunotherapy of Cancer, 5(1), 91.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"9992_CR61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","volume":"3","author":"BP Geisler","year":"2015","unstructured":"Geisler, B. P., Raad, R. A., Esaian, D., Sharon, E., & Schwartz, D. R. (2015). Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. Journal for Immunotherapy of Cancer, 3(1), 4.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"9992_CR62","unstructured":"Ederhy, S., Cautela, J., Ancedy, Y., Escudier, M., Thuny, F., & Cohen, A. (2018). Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC: Cardiovascular Imaging, 2517."},{"issue":"13","key":"9992_CR63","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1161\/CIRCULATIONAHA.118.037975","volume":"139","author":"C Scally","year":"2019","unstructured":"Scally, C., Abbas, H., Ahearn, T., Srinivasan, J., Mezincescu, A., Rudd, A., et al. (2019). Myocardial and systemic inflammation in acute stress-induced (Takotsubo) cardiomyopathy. Circulation., 139(13), 1581\u20131592.","journal-title":"Circulation."},{"issue":"1","key":"9992_CR64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/toxsci\/kfv210","volume":"149","author":"DM Kim","year":"2016","unstructured":"Kim, D. M., Kim, H., Yeon, J. H., Lee, J. H., & Park, H. O. (2016). Identification of a mitochondrial DNA polymerase affecting cardiotoxicity of sunitinib using a genome-wide screening on S. pombe deletion library. Toxicological Sciences, 149(1), 4\u201314.","journal-title":"Toxicological Sciences"},{"key":"9992_CR65","doi-asserted-by":"crossref","unstructured":"Hudson G, Chinnery PF. Mitochondrial DNA polymerase-gamma and human disease. Hum Mol Genet. 2006;15 Spec No 2:R244\u201352.","DOI":"10.1093\/hmg\/ddl233"},{"issue":"3","key":"9992_CR66","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ccr.2009.12.046","volume":"17","author":"SA Martin","year":"2010","unstructured":"Martin, S. A., McCabe, N., Mullarkey, M., Cummins, R., Burgess, D. J., Nakabeppu, Y., et al. (2010). DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell, 17(3), 235\u2013248.","journal-title":"Cancer Cell"},{"issue":"3","key":"9992_CR67","doi-asserted-by":"crossref","first-page":"C695","DOI":"10.1152\/ajpcell.00322.2010","volume":"301","author":"Y Wang","year":"2011","unstructured":"Wang, Y., Zang, Q. S., Liu, Z., Wu, Q., Maass, D., Dulan, G., et al. (2011). Regulation of VEGF-induced endothelial cell migration by mitochondrial reactive oxygen species. American Journal of Physiology. Cell Physiology, 301(3), C695\u2013C704.","journal-title":"American Journal of Physiology. Cell Physiology"},{"issue":"5","key":"9992_CR68","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bbabio.2008.10.007","volume":"1787","author":"SS Chan","year":"2009","unstructured":"Chan, S. S., & Copeland, W. C. (2009). DNA polymerase gamma and mitochondrial disease: understanding the consequence of POLG mutations. Biochimica et Biophysica Acta, 1787(5), 312\u2013319.","journal-title":"Biochimica et Biophysica Acta"},{"issue":"2","key":"9992_CR69","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","volume":"13","author":"L Fagerberg","year":"2014","unstructured":"Fagerberg, L., Hallstr\u00f6m, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., et al. (2014). Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Molecular & Cellular Proteomics, 13(2), 397\u2013406.","journal-title":"Molecular & Cellular Proteomics"},{"issue":"Pt 12","key":"9992_CR70","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1093\/brain\/aws298","volume":"135","author":"VC Neeve","year":"2012","unstructured":"Neeve, V. C., Samuels, D. C., Bindoff, L. A., van den Bosch, B., Van Goethem, G., Smeets, H., et al. (2012). What is influencing the phenotype of the common homozygous polymerase-\u03b3 mutation p.Ala467Thr? Brain., 135(Pt 12), 3614\u20133626.","journal-title":"Brain."},{"issue":"9529","key":"9992_CR71","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(06)68970-8","volume":"368","author":"AH Schapira","year":"2006","unstructured":"Schapira, A. H. (2006). Mitochondrial disease. Lancet., 368(9529), 70\u201382.","journal-title":"Lancet."},{"key":"9992_CR72","doi-asserted-by":"crossref","unstructured":"Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, et al. Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart and suggest cardiotoxicity from combined signal transducer and activator of transcription and epidermal growth factor receptor inhibition. J Am Heart Assoc. 2017;6(10).","DOI":"10.1161\/JAHA.117.006635"},{"key":"9992_CR73","doi-asserted-by":"crossref","unstructured":"Jensen BC, Parry TL, Huang W, Ilaiwy A, Bain JR, Muehlbauer MJ, et al. Non-targeted metabolomics analysis of the effects of tyrosine kinase inhibitors sunitinib and erlotinib on heart, muscle, liver and serum metabolism in vivo. Metabolites. 2017;7(3).","DOI":"10.3390\/metabo7030031"},{"key":"9992_CR74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxlet.2015.11.007","volume":"241","author":"AJ Blanca","year":"2016","unstructured":"Blanca, A. J., Ruiz-Armenta, M. V., Zambrano, S., Miguel-Carrasco, J. L., Arias, J. L., Ar\u00e9valo, M., et al. (2016). Inflammatory and fibrotic processes are involved in the cardiotoxic effect of sunitinib: protective role of L-carnitine. Toxicology Letters, 241, 9\u201318.","journal-title":"Toxicology Letters"},{"issue":"2","key":"9992_CR75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine, 353(2), 123\u2013132.","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"9992_CR76","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12944-016-0366-5","volume":"15","author":"ZH Yang","year":"2016","unstructured":"Yang, Z. H., Emma-Okon, B., & Remaley, A. T. (2016). Dietary marine-derived long-chain monounsaturated fatty acids and cardiovascular disease risk: a mini review. Lipids in Health and Disease, 15(1), 201.","journal-title":"Lipids in Health and Disease"},{"issue":"11","key":"9992_CR77","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.7150\/thno.19551","volume":"7","author":"J Sourdon","year":"2017","unstructured":"Sourdon, J., Lager, F., Viel, T., Balvay, D., Moorhouse, R., Bennana, E., et al. (2017). Cardiac metabolic deregulation induced by the tyrosine kinase receptor inhibitor sunitinib is rescued by endothelin receptor antagonism. Theranostics., 7(11), 2757\u20132774.","journal-title":"Theranostics."},{"issue":"10","key":"9992_CR78","doi-asserted-by":"crossref","first-page":"e006635","DOI":"10.1161\/JAHA.117.006635","volume":"6","author":"TJ Stuhlmiller","year":"2017","unstructured":"Stuhlmiller, T. J., Zawistowski, J. S., Chen, X., Sciaky, N., Angus, S. P., Hicks, S. T., et al. (2017). Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart and suggest cardiotoxicity from combined signal transducer and activator of transcription and epidermal growth factor receptor inhibition. Journal of the American Heart Association, 6(10), e006635.","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"9992_CR79","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/toxsci\/kfx082","volume":"158","author":"SD Lamore","year":"2017","unstructured":"Lamore, S. D., Ahlberg, E., Boyer, S., Lamb, M. L., Hortigon-Vinagre, M. P., Rodriguez, V., et al. (2017). Deconvoluting kinase inhibitor induced cardiotoxicity. Toxicological Sciences, 158(1), 213\u2013226.","journal-title":"Toxicological Sciences"},{"key":"9992_CR80","doi-asserted-by":"crossref","first-page":"20211","DOI":"10.1039\/C8RA02877J","volume":"8","author":"G Suvendu","year":"2018","unstructured":"Suvendu, G., Manivannan, J., Srinivasan, B., Sundaresan, L., Gajalakshmib, P., & Chatterjee, S. (2018). A proteome-wide systems toxicological approach deciphers the interaction network of chemotherapeutic drugs in the cardiovascular milieu. RSC Advances, 8, 20211\u201320221.","journal-title":"RSC Advances"},{"issue":"4","key":"9992_CR81","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1053\/j.gastro.2008.06.077","volume":"135","author":"BD Juran","year":"2008","unstructured":"Juran, B. D., Atkinson, E. J., Schlicht, E. M., Fridley, B. L., & Lazaridis, K. N. (2008). Primary biliary cirrhosis is associated with a genetic variant in the 3\u2032 flanking region of the CTLA4 gene. Gastroenterology, 135(4), 1200\u20131206.","journal-title":"Gastroenterology"},{"issue":"4","key":"9992_CR82","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1089\/gtmb.2016.0335","volume":"21","author":"K Wang","year":"2017","unstructured":"Wang, K., Zhu, Q., Lu, Y., Lu, H., Zhang, F., Wang, X., et al. (2017). CTLA-4 +49 G\/a polymorphism confers autoimmune disease risk: an updated meta-analysis. Genetic Testing and Molecular Biomarkers, 21(4), 222\u2013227.","journal-title":"Genetic Testing and Molecular Biomarkers"},{"issue":"7","key":"9992_CR83","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/hmg\/5.7.1075","volume":"5","author":"L Nistic\u00f2","year":"1996","unstructured":"Nistic\u00f2, L., Buzzetti, R., Pritchard, L. E., Van der Auwera, B., Giovannini, C., Bosi, E., et al. (1996). The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Human Molecular Genetics, 5(7), 1075\u20131080.","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"9992_CR84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/gut.43.2.187","volume":"43","author":"I Djilali-Saiah","year":"1998","unstructured":"Djilali-Saiah, I., Schmitz, J., Harfouch-Hammoud, E., Mougenot, J. F., Bach, J. F., & Caillat-Zucman, S. (1998). CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut., 43(2), 187\u2013189.","journal-title":"Gut."},{"issue":"9","key":"9992_CR85","doi-asserted-by":"crossref","first-page":"9159","DOI":"10.1007\/s11033-012-1788-4","volume":"39","author":"WW Chang","year":"2012","unstructured":"Chang, W. W., Zhang, L., Yao, Y. S., & Su, H. (2012). Association between CTLA-4 exon-1 +49A\/G polymorphism and systemic lupus erythematosus: an updated analysis. Molecular Biology Reports, 39(9), 9159\u20139165.","journal-title":"Molecular Biology Reports"},{"issue":"3","key":"9992_CR86","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s12013-013-9640-6","volume":"67","author":"N Torres-Carrillo","year":"2013","unstructured":"Torres-Carrillo, N., Ontiveros-Mercado, H., Torres-Carrillo, N. M., Parra-Rojas, I., Rangel-Villalobos, H., Ram\u00edrez-Due\u00f1as, M. G., et al. (2013). The -319C\/+49G\/CT60G haplotype of CTLA-4 gene confers susceptibility to rheumatoid arthritis in Mexican population. Cell Biochemistry and Biophysics, 67(3), 1217\u20131228.","journal-title":"Cell Biochemistry and Biophysics"},{"issue":"3","key":"9992_CR87","doi-asserted-by":"crossref","first-page":"e0149441","DOI":"10.1371\/journal.pone.0149441","volume":"11","author":"H Patel","year":"2016","unstructured":"Patel, H., Mansuri, M. S., Singh, M., Begum, R., Shastri, M., & Misra, A. (2016). Association of cytotoxic T-lymphocyte antigen 4 (CTLA4) and thyroglobulin (TG) genetic variants with autoimmune hypothyroidism. PLoS One, 11(3), e0149441.","journal-title":"PLoS One"},{"issue":"2","key":"9992_CR88","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1755-148X.2009.00543.x","volume":"22","author":"SA Birlea","year":"2009","unstructured":"Birlea, S. A., Laberge, G. S., Procopciuc, L. M., Fain, P. R., & Spritz, R. A. (2009). CTLA4 and generalized vitiligo: two genetic association studies and a meta-analysis of published data. Pigment Cell & Melanoma Research, 22(2), 230\u2013234.","journal-title":"Pigment Cell & Melanoma Research"},{"issue":"6","key":"9992_CR89","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/er.2008-0015","volume":"29","author":"A Huber","year":"2008","unstructured":"Huber, A., Menconi, F., Corathers, S., Jacobson, E. M., & Tomer, Y. (2008). Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocrine Reviews, 29(6), 697\u2013725.","journal-title":"Endocrine Reviews"},{"key":"9992_CR90","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2350-11-91","volume":"11","author":"O Hradsky","year":"2010","unstructured":"Hradsky, O., Dusatkova, P., Lenicek, M., Bronsky, J., Nevoral, J., Vitek, L., et al. (2010). The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn's disease. BMC Medical Genetics, 11, 91.","journal-title":"BMC Medical Genetics"},{"issue":"7","key":"9992_CR91","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1440-1746.2012.07118.x","volume":"27","author":"M Li","year":"2012","unstructured":"Li, M., Zheng, H., Li, T., Gao, P., Zhang, X. L., & Liu, D. W. (2012). Cytotoxic T-lymphocyte associated antigen-4 gene polymorphisms and primary biliary cirrhosis: a systematic review. Journal of Gastroenterology and Hepatology, 27(7), 1159\u20131166.","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"23","key":"9992_CR92","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., et al. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine, 371(23), 2189\u20132199.","journal-title":"The New England Journal of Medicine"},{"issue":"6257","key":"9992_CR93","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., et al. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science., 350(6257), 207\u2013211.","journal-title":"Science."},{"issue":"1","key":"9992_CR94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2017-0519","volume":"24","author":"V Subbiah","year":"2019","unstructured":"Subbiah, V., & Kurzrock, R. (2019). The marriage between genomics and immunotherapy: mismatch meets its match. Oncologist., 24(1), 1\u20133.","journal-title":"Oncologist."},{"issue":"5","key":"9992_CR95","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., et al. (2018). Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell, 33(5), 843\u201352.e4.","journal-title":"Cancer Cell"},{"issue":"1","key":"9992_CR96","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41467-017-01018-0","volume":"8","author":"CY Ock","year":"2017","unstructured":"Ock, C. Y., Hwang, J. E., Keam, B., Kim, S. B., Shim, J. J., Jang, H. J., et al. (2017). Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nature Communications, 8(1), 1050.","journal-title":"Nature Communications"},{"issue":"1","key":"9992_CR97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., et al. (2016). Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell, 165(1), 35\u201344.","journal-title":"Cell"},{"issue":"3","key":"9992_CR98","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., et al. (2019). Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature Medicine, 25(3), 462\u2013469.","journal-title":"Nature Medicine"},{"key":"9992_CR99","doi-asserted-by":"crossref","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411).","DOI":"10.1126\/science.aar3593"},{"issue":"1","key":"9992_CR100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12885-018-4134-y","volume":"18","author":"KA Brogden","year":"2018","unstructured":"Brogden, K. A., Parashar, D., Hallier, A. R., Braun, T., Qian, F., Rizvi, N. A., et al. (2018). Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer, 18(1), 225.","journal-title":"BMC Cancer"},{"key":"9992_CR101","doi-asserted-by":"crossref","unstructured":"Goltz D, Gevensleben H, Vogt TJ, Dietrich J, Golletz C, Bootz F, et al. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients. JCI Insight. 2018;3(13).","DOI":"10.1172\/jci.insight.96793"},{"issue":"6","key":"9992_CR102","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/ATVBAHA.119.312193","volume":"39","author":"A Zarzour","year":"2019","unstructured":"Zarzour, A., Kim, H. W., & Weintraub, N. L. (2019). Epigenetic regulation of vascular diseases. Arteriosclerosis, Thrombosis, and Vascular Biology, 39(6), 984\u2013990.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"9","key":"9992_CR103","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrcardio.2010.104","volume":"7","author":"JM Ordov\u00e1s","year":"2010","unstructured":"Ordov\u00e1s, J. M., & Smith, C. E. (2010). Epigenetics and cardiovascular disease. Nature Reviews. Cardiology, 7(9), 510\u2013519.","journal-title":"Nature Reviews. Cardiology"},{"issue":"6371","key":"9992_CR104","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., et al. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science., 359(6371), 97\u2013103.","journal-title":"Science."},{"issue":"1","key":"9992_CR105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-018-0592-6","volume":"11","author":"M Yi","year":"2018","unstructured":"Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., et al. (2018). Gut microbiome modulates efficacy of immune checkpoint inhibitors. Journal of Hematology & Oncology, 11(1), 47.","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"9992_CR106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40169-019-0225-x","volume":"8","author":"J Gong","year":"2019","unstructured":"Gong, J., Chehrazi-Raffle, A., Placencio-Hickok, V., Guan, M., Hendifar, A., & Salgia, R. (2019). The gut microbiome and response to immune checkpoint inhibitors: Preclinical and clinical strategies. Clinical and Translational Medicine, 8(1), 9.","journal-title":"Clinical and Translational Medicine"},{"issue":"5","key":"9992_CR107","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.kint.2018.03.003","volume":"93","author":"GJ Silverman","year":"2018","unstructured":"Silverman, G. J., Azzouz, D. F., & Mor, A. (2018). Immune checkpoint inhibitors and the union of bugs against cancer. Kidney International, 93(5), 1030\u20131032.","journal-title":"Kidney International"},{"issue":"6371","key":"9992_CR108","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daill\u00e8re, R., et al. (2018). Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science., 359(6371), 91\u201397.","journal-title":"Science."},{"issue":"6371","key":"9992_CR109","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M. L., et al. (2018). The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science., 359(6371), 104\u2013108.","journal-title":"Science."},{"key":"9992_CR110","doi-asserted-by":"crossref","unstructured":"Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, et al. Gut microbiota and cancer: from pathogenesis to therapy. Cancers (Basel). 2019;11(1).","DOI":"10.3390\/cancers11010038"},{"issue":"4","key":"9992_CR111","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2967\/jnumed.118.220137","volume":"60","author":"AD Dreyfuss","year":"2019","unstructured":"Dreyfuss, A. D., Bravo, P. E., Koumenis, C., & Ky, B. (2019). Precision cardio-oncology. Journal of Nuclear Medicine, 60(4), 443\u2013450.","journal-title":"Journal of Nuclear Medicine"},{"key":"9992_CR112","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"J Salem","year":"2019","unstructured":"Salem, J., Allenbach, Y., Vozy, A., Brechot, N., Johnson, D., Moslehi, J., et al. (2019). Abatacept for severe immune checkpoint inhibitor\u2013associated myocarditis. The New England Journal of Medicine, 380, 2377\u20132379.","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"9992_CR113","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","volume":"4","author":"AN Shoushtari","year":"2018","unstructured":"Shoushtari, A. N., Friedman, C. F., Navid-Azarbaijani, P., Postow, M. A., Callahan, M. K., Momtaz, P., et al. (2018). Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncology, 4(1), 98\u2013101.","journal-title":"JAMA Oncology"},{"issue":"9","key":"9992_CR114","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","volume":"20","author":"G Di Lorenzo","year":"2009","unstructured":"Di Lorenzo, G., Autorino, R., Bruni, G., Carten\u00ec, G., Ricevuto, E., Tudini, M., et al. (2009). Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Annals of Oncology, 20(9), 1535\u20131542.","journal-title":"Annals of Oncology"},{"issue":"13","key":"9992_CR115","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","volume":"133","author":"J Herrmann","year":"2016","unstructured":"Herrmann, J., Yang, E. H., Iliescu, C. A., Cilingiroglu, M., Charitakis, K., Hakeem, A., et al. (2016). Vascular toxicities of cancer therapies: the old and the new--an evolving avenue. Circulation., 133(13), 1272\u20131289.","journal-title":"Circulation."},{"issue":"suppl_4","key":"9992_CR116","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., et al. (2017). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 28(suppl_4), iv119\u2013iiv42.","journal-title":"Annals of Oncology"},{"issue":"8","key":"9992_CR117","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1634\/theoncologist.2018-0157","volume":"23","author":"TG Neilan","year":"2018","unstructured":"Neilan, T. G., Rothenberg, M. L., Amiri-Kordestani, L., Sullivan, R. J., Steingart, R. M., Gregory, W., et al. (2018). Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist., 23(8), 874\u2013878.","journal-title":"Oncologist."}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-020-09992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12265-020-09992-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-020-09992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:21:52Z","timestamp":1617668512000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12265-020-09992-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":117,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["9992"],"URL":"https:\/\/doi.org\/10.1007\/s12265-020-09992-5","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,6]]},"assertion":[{"value":"31 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}